JP Morgan Initiates Coverage On Spyre Therapeutics with Overweight Rating, Announces Price Target of $110

JP Morgan analyst Hardik Parikh has initiated coverage on Spyre Therapeutics (NASDAQ: SYRE) with an Overweight rating. The firm has set a price target of $110 for the stock.